Lv41
410 积分 2021-12-21 加入
Non-alcoholic fatty liver disease
2个月前
已完结
YAP/TAZ as master regulators in liver regeneration and disease: insights into mechanisms and therapeutic targets
2个月前
已完结
Nonalcoholic fatty liver disease: lifestyle and quality of life
2个月前
已完结
Imbalance in ALR ubiquitination accelerates the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma
2个月前
已完结
Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease
2个月前
已完结
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
2个月前
已完结
Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges
2个月前
已完结
Resmetirom: The First FDA-Approved Drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with a Perspective on Precision Medicine
2个月前
已完结
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
2个月前
已完结
Hypoxia, Psychedelics, and Terminal Lucidity: A Perspective on Neuroplasticity and Neuropsychiatric Disorders
3个月前
已完结
皖公网安备34019202002308
